ERBB2 and breast cancer: To answer this and other queries, the DESTINY-Breast05 is continuing investigation as an ongoing phase III, randomized, active-controlled trial of T-DXd versus T-DM1 in HER2+ BC patients, with high-risk features for disease relapse, who have residual invasive disease in the breast and/or axilla after NAC completion [128].